Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Captrust Financial Advisors purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 12,629 shares of the company’s stock, valued at approximately $403,000.

Several other institutional investors have also recently made changes to their positions in APLS. Baird Financial Group Inc. lifted its position in shares of Apellis Pharmaceuticals by 101.2% during the 4th quarter. Baird Financial Group Inc. now owns 54,665 shares of the company’s stock valued at $1,744,000 after buying an additional 27,495 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in shares of Apellis Pharmaceuticals by 1,388.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 744,194 shares of the company’s stock worth $23,747,000 after purchasing an additional 694,194 shares during the period. Bank of America Corp DE boosted its position in shares of Apellis Pharmaceuticals by 72.3% in the fourth quarter. Bank of America Corp DE now owns 1,680,213 shares of the company’s stock worth $53,616,000 after purchasing an additional 705,209 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Apellis Pharmaceuticals by 432.8% in the fourth quarter. BNP Paribas Financial Markets now owns 850,823 shares of the company’s stock worth $27,150,000 after purchasing an additional 691,123 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Apellis Pharmaceuticals by 2.6% during the 4th quarter. Ameriprise Financial Inc. now owns 882,801 shares of the company’s stock valued at $28,170,000 after purchasing an additional 22,507 shares during the period. Institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on APLS. Wells Fargo & Company decreased their target price on Apellis Pharmaceuticals from $30.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 8th. Wedbush reduced their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Needham & Company LLC dropped their target price on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lifted their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Finally, Scotiabank decreased their price target on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a research note on Thursday, May 8th. Nine analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $40.42.

Apellis Pharmaceuticals Trading Up 1.3%

APLS opened at $17.67 on Tuesday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $43.99. The business’s 50 day moving average is $20.17 and its two-hundred day moving average is $26.62. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of -8.70 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same period in the previous year, the firm posted ($0.54) EPS. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. On average, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now directly owns 138,730 shares in the company, valued at approximately $3,482,123. This represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.50% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).